IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis - Episode 12

Safety Data With Biologics in Atopic Dermatitis

Published on: February 18, 2025

Linda Stein Gold, MD, Alexandra K. Golant, MD, Peter Lio, MD

Panelists discuss the safety of biologics in atopic dermatitis (AD), reviewing current understanding of their safety profiles, including long-term data, adverse events, and the overall risk-benefit analysis for patients using these agents.

EP. 1: Heterogenous Presentation Of Atopic Dermatitis

EP. 2: Use of Biopsy and Diagnosing New-Onset AD

EP. 3: Treatment Options in Atopic Dermatitis

EP. 4: Improvement in Standard of Care in Atopic Dermatitis

EP. 5: Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP. 6: Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP. 7: IL-13–Targeting Agents in Atopic dermatitis

EP. 8: Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP. 9: Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP. 10: Switching or Staying Within the Treatment Class

EP. 11: Use of Combination Therapy in Atopic Dermatitis

Now Viewing

EP. 12: Safety Data With Biologics in Atopic Dermatitis

EP. 13: Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

EP. 14: Lebrikizumab in Patients With Skin of Color (ADmirable)

EP. 15: Treatment Nonresponders in Atopic Dermatitis

EP. 16: Considerations for Switching Treatment

EP. 17: Emerging Treatment Options in Atopic Dermatitis

Video content above is prompted by the following:

Please discuss the safety of biologics in AD. Where are we today in understanding the safety of these agents?